Sartorius AG (SOAGY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sartorius AG (SOAGY) trades at $52.23 with AI Score 45/100 (Grade C). Sartorius AG is a leading international partner of the biopharmaceutical industry and laboratories. Market cap: $76.31B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for SOAGY: SOAGY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SOAGY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SOAGY: the 1 perspectives are evenly split.
How is this calculated? →Sartorius AG (SOAGY) Healthcare & Pipeline Overview
Sartorius AG, a German-based company, provides bioprocess solutions and lab products to the biopharmaceutical industry and research institutions. With a market capitalization of $76.31B, Sartorius focuses on innovative technologies for drug development and manufacturing, operating in the life science research, biopharmaceutical manufacturing, and applied industries.
What Is the Investment Thesis for SOAGY?
Sartorius AG presents a notable research candidate due to its strong market position and growth prospects within the biopharmaceutical industry. The company's comprehensive product portfolio and technological expertise enable it to capitalize on the increasing demand for bioprocess solutions. With a current P/E ratio of 90.4 and a profit margin of 4.4%, Sartorius demonstrates potential for improved profitability through operational efficiencies and economies of scale. Key growth catalysts include the expansion of the biopharmaceutical market, increasing demand for single-use technologies, and strategic acquisitions. However, investors may want to evaluate the potential risks associated with currency fluctuations and competition. The company's beta of 1.51 indicates higher volatility compared to the overall market.
Based on FMP financials and quantitative analysis
SOAGY Key Highlights
- Market capitalization of $76.31B, reflecting its significant presence in the bioprocess solutions market.
- P/E ratio of 90.4, indicating investor expectations of future earnings growth.
- Gross margin of 46.3%, showcasing its ability to maintain profitability in a competitive market.
- Dividend yield of 0.35%, providing a modest return to shareholders.
- Beta of 1.51, suggesting higher volatility compared to the market average.
Who Are SOAGY's Competitors?
SOAGY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CHGCF Chugai Pharmaceutical Co., Ltd. | $46.51 | +0.93% | $76.54B | 55 |
| CHGCY Chugai Pharmaceutical Co., Ltd. | $23.26 | -0.47% | $76.56B | 55 |
| GLAXF GSK plc | $25.30 | -1.82% | $101.34B | 58 |
| HOCPF HOYA Corporation | $154.58 | -8.26% | $51.71B | — |
| HOCPY HOYA Corporation | $158.60 | +0.48% | $53.05B | 56 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| STXS Stereotaxis, Inc. | $1.88 | +5.03% | $183.74M | 60 |
| IVTY Invuity, Inc. | $7.39 | +0.00% | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SOAGY's Key Strengths?
- Strong market position in bioprocess solutions.
- Comprehensive product portfolio.
- Technological expertise and innovation.
- Global sales and service network.
What Are SOAGY's Weaknesses?
- High P/E ratio compared to industry peers.
- Dependence on the biopharmaceutical industry.
- Exposure to currency fluctuations.
What Could Drive SOAGY Stock Higher?
- Increasing demand for bioprocess solutions driven by the growth of the biopharmaceutical industry.
- Expansion of cell and gene therapy manufacturing solutions.
- Potential strategic acquisitions to expand product portfolio and geographic reach.
- Adoption of single-use technologies in biopharmaceutical manufacturing.
- Leveraging data analytics and process analytical technology (PAT) to optimize biopharmaceutical manufacturing processes.
What Are the Key Risks for SOAGY?
- Rich valuation — a P/E of 90.4 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Intense competition from other bioprocess solution providers.
- Exposure to currency fluctuations.
- Regulatory changes impacting the biopharmaceutical industry.
- Economic downturns affecting demand for bioprocess solutions.
- Technological obsolescence.
What Are the Growth Opportunities for SOAGY?
- Growth opportunity 1: Expansion of cell and gene therapy manufacturing solutions represents a significant growth opportunity for Sartorius. The cell and gene therapy market is projected to reach $36.9 billion by 2027, growing at a CAGR of 33.9% from 2021. Sartorius can leverage its expertise in cell culture and bioprocessing to provide integrated solutions for cell and gene therapy manufacturing, including bioreactors, cell culture media, and process development services. This expansion allows Sartorius to capture a larger share of the rapidly growing market.
- Growth opportunity 2: Increasing adoption of single-use technologies in biopharmaceutical manufacturing offers another avenue for growth. Single-use technologies, such as disposable bioreactors and filtration systems, offer advantages in terms of reduced cleaning and sterilization costs, as well as improved flexibility and scalability. The global single-use bioprocessing market is expected to reach $12.5 billion by 2028. Sartorius is well-positioned to capitalize on this trend with its comprehensive portfolio of single-use products and solutions.
- Growth opportunity 3: Strategic acquisitions can drive growth by expanding Sartorius's product portfolio and geographic reach. Sartorius has a history of successful acquisitions, such as the acquisition of Albumedix in 2022, which expanded its offering of innovative solutions for biopharmaceutical manufacturing. By acquiring complementary businesses, Sartorius can strengthen its market position and accelerate growth. The company can target companies with innovative technologies or strong market presence in specific geographic regions.
- Growth opportunity 4: Leveraging data analytics and process analytical technology (PAT) to optimize biopharmaceutical manufacturing processes. The application of data analytics and PAT can improve process efficiency, reduce costs, and enhance product quality. Sartorius offers a range of PAT solutions and data analytics tools that enable biopharmaceutical manufacturers to gain insights into their processes and optimize performance. The company can further develop its capabilities in this area to provide more comprehensive solutions to its customers.
- Growth opportunity 5: Expanding its presence in emerging markets, such as Asia-Pacific and Latin America, offers significant growth potential. These markets are experiencing rapid growth in biopharmaceutical manufacturing, driven by increasing healthcare spending and growing demand for biologics. Sartorius can leverage its global sales and service network to expand its presence in these markets and capture a larger share of the growing demand. This includes establishing local manufacturing facilities and partnerships to better serve customers in these regions.
What Opportunities Does SOAGY Have?
- Expansion of cell and gene therapy manufacturing solutions.
- Increasing adoption of single-use technologies.
- Strategic acquisitions.
- Growth in emerging markets.
What Threats Does SOAGY Face?
- Intense competition.
- Regulatory changes.
- Economic downturns.
- Technological obsolescence.
What Are SOAGY's Competitive Advantages?
- Strong brand reputation and customer relationships in the biopharmaceutical industry.
- Extensive product portfolio covering a wide range of bioprocess applications.
- Technological expertise and innovation in bioprocess solutions.
- Global sales and service network providing local support to customers.
- High switching costs for customers due to regulatory requirements and validation processes.
What Does SOAGY Do?
Founded in 1870 and headquartered in Göttingen, Germany, Sartorius Aktiengesellschaft has evolved into a global leader in bioprocess solutions and lab products and services. Initially focused on precision balances, the company transitioned to filtration technology in the early 20th century, a move that laid the foundation for its current position in the biopharmaceutical industry. Today, Sartorius offers a comprehensive range of products, including bioreactors, filtration systems, cell culture media, and lab instruments. These products are essential for biopharmaceutical companies in developing and manufacturing drugs, vaccines, and other biologics. Sartorius serves a diverse customer base, including life science research institutions, biopharmaceutical manufacturers, and quality control laboratories. The company's global presence spans Europe, North America, and Asia, with manufacturing facilities and sales offices strategically located to serve key markets. Sartorius's competitive advantage lies in its broad product portfolio, technological expertise, and strong customer relationships. The company continues to invest in research and development to innovate new solutions for the biopharmaceutical industry.
What Products and Services Does SOAGY Offer?
- Provides bioprocess solutions for the biopharmaceutical industry.
- Offers lab products and services for research and quality control.
- Develops and manufactures bioreactors for cell culture and fermentation.
- Supplies filtration systems for purification and separation.
- Offers cell culture media and reagents for cell growth and maintenance.
- Provides process analytical technology (PAT) and data analytics solutions.
- Manufactures weighing systems, pipetting, and dispensing systems for laboratories.
How Does SOAGY Make Money?
- Sells bioprocess equipment and consumables to biopharmaceutical manufacturers.
- Provides lab products and services to research institutions and quality control laboratories.
- Offers bioprocess development and engineering services.
- Generates revenue through product sales, service contracts, and licensing agreements.
What Industry Does SOAGY Operate In?
Sartorius AG operates in the rapidly growing biopharmaceutical industry, driven by increasing demand for biologics and personalized medicine. The market for bioprocess solutions is expected to continue expanding, fueled by advancements in cell and gene therapy, as well as the need for efficient and scalable manufacturing processes. Sartorius competes with companies such as CHGCF (Cytiva) and GLAXF (GlaxoSmithKline) in providing bioprocess equipment and services. The industry is characterized by technological innovation, regulatory scrutiny, and the need for specialized expertise.
Who Are SOAGY's Key Customers?
- Biopharmaceutical companies developing and manufacturing drugs and vaccines.
- Life science research institutions conducting basic and applied research.
- Quality control laboratories testing pharmaceutical products.
- Applied industries such as food and beverage.
How Sartorius AG Is Valued
Sartorius AG carries a market capitalization of $76.31B, placing it in the large-cap category. Relative to its peer group, SOAGY's quantitative score of 45/100 is below the peer average of 56/100.
Company Profile
Sartorius AG operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Göttingen, DE. The company is led by CEO Michael Grosse. SOAGY has traded publicly since 2020.
ROE 6%Key Financial Metrics
Return on equity for Sartorius AG stands at 6.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.6%, showing how much profit it generates from its asset base. SOAGY trades at a trailing price-to-earnings ratio of 90.40, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.91 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 1.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Sartorius AG's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 7.35 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Sartorius AG revenue of about $3.75B for fiscal 2026, with EPS near $0.00. The estimate reflects 22 contributing analysts.
SOAGY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong market position in bioprocess solutions.
- Comprehensive product portfolio.
- Technological expertise and innovation.
- Global sales and service network.
Bear Case
- High P/E ratio compared to industry peers.
- Dependence on the biopharmaceutical industry.
- Exposure to currency fluctuations.
- Potential: Intense competition from other bioprocess solution providers.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
SOAGY Latest News
No recent news available for SOAGY.
SOAGY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SOAGY.
Price Targets
Wall Street price target analysis for SOAGY.
SOAGY MoonshotScore
What does this score mean?
The MoonshotScore rates SOAGY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael Grosse
Chief Executive Officer
Michael Grosse has served as the Chief Executive Officer of Sartorius AG since 2011. Prior to joining Sartorius, he held various leadership positions at Bayer AG and Lanxess AG. He holds a Ph.D. in chemical engineering from RWTH Aachen University. Grosse's extensive experience in the chemical and pharmaceutical industries has been instrumental in driving Sartorius's growth and strategic direction.
Track Record: Under Michael Grosse's leadership, Sartorius has experienced significant growth and expansion. He has overseen several strategic acquisitions, including the acquisition of Albumedix, which have strengthened the company's market position. Grosse has also focused on innovation and the development of new bioprocess solutions, driving the company's technological leadership. Sartorius has also significantly increased its market capitalization during his tenure.
Sartorius AG ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. SOAGY is a Level 1 ADR, meaning it trades over-the-counter (OTC) rather than on a major exchange. This allows U.S. investors to invest in Sartorius AG without dealing with foreign exchanges.
- Home Market Ticker: Frankfurt Stock Exchange (SOAG), Germany
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SOAG
SOAGY OTC Market Information
SOAGY trades on the OTC Other tier, which represents the lowest tier of the OTC market. Companies on this tier often have limited or no financial disclosure requirements and may not meet the listing standards of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of transparency and regulatory oversight compared to listed companies. This tier is generally reserved for companies with limited operating history, distressed financials, or those that choose not to comply with stricter exchange requirements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Greater price volatility.
- Potential for fraud or manipulation.
- Higher risk of delisting or going out of business.
- Verify the company's legal status and registration.
- Obtain and review the company's financial statements, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Established presence in the biopharmaceutical industry.
- Global sales and service network.
- Technological expertise and innovation.
- Compliance with German regulatory requirements.
- Listing on the Frankfurt Stock Exchange (SOAG).
What Investors Ask About Sartorius AG (SOAGY) — Healthcare
What does Sartorius AG do?
Sartorius AG is a leading international partner of the biopharmaceutical industry and laboratories, providing bioprocess solutions and lab products and services. The company offers a comprehensive range of products, including bioreactors, filtration systems, cell culture media, and lab instruments, which are essential for biopharmaceutical companies in developing and manufacturing drugs, vaccines, and other biologics. Sartorius serves a diverse customer base, including life science research institutions, biopharmaceutical manufacturers, and quality control laboratories.
What are the main risks for SOAGY?
The main risks for SOAGY include intense competition from other bioprocess solution providers, exposure to currency fluctuations, regulatory changes impacting the biopharmaceutical industry, economic downturns affecting demand for bioprocess solutions, and technological obsolescence. Additionally, as an OTC stock, SOAGY is subject to risks associated with limited financial disclosure, lower trading volume, and greater price volatility. Investors should carefully consider these risks before investing in SOAGY.
What are the key factors to evaluate for SOAGY?
Sartorius AG (SOAGY) holds an AI score of 45/100 (low). P/E: 90.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does SOAGY data refresh on this page?
SOAGY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SOAGY's recent stock price performance?
Sartorius AG (SOAGY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in bioprocess solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SOAGY overvalued or undervalued right now?
Sartorius AG (SOAGY) trades at 90.4x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SOAGY?
Before investing in Sartorius AG (SOAGY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SOAGY to a portfolio?
Key strength of Sartorius AG (SOAGY): Strong market position in bioprocess solutions. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for SOAGY. The information provided is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than data for listed companies.